News

As society continues to become more technologically advanced and patient expectations grow alongside, there is no better time for physicians to rework the antiquated eyedrop-centered glaucoma treatment regime. SLT offers the treatment efficacy and convenience patients today need and stands to give the 1970s-based management of glaucoma a long-awaited shake-up in the 2010s.

Early problems associated with femtosecond laser-assisted refractive cataract surgery have been successfully downsized thanks to ongoing platform improvements and the introduction of new surgical instruments and techniques.

A new eye vitamin and mineral supplement was introduced by Bausch + Lomb at the 2013 American Society of Retina Specialists annual meeting.

Second Sight Medical Products Inc.’s retinal prosthesis system has been approved by the Centers for Medicare and Medicaid Services (CMS) for both inpatient and outpatient settings of care payments beginning Oct. 1.

In comparing conventional slit lamp photography with iPhone images, it was found the smartphone produces higher quality pictures and in a more economical way.

Words to live by

John of Garland, writing some 900 years ago, provided excellent advice to the young persons of his time-advice that we ophthalmologists today would be wise to heed.

Clinicians share their thoughts on the roles of a dual-acting antihistamine/mast cell stabilizer and topical ester corticosteroid in the management of seasonal allergic conjunctivitis.

Utilizing a red eye protocol can be helpful in the determination of whether conjunctivitis is allergic, viral, or bacterial.

Recent data show that although ocular allergies are common, the majority of sufferers do not seek medical help beyond over-the-counter drugs.

Patients who receive intravitreal ranibizumab (Lucentis, Genentech) for treatment of diabetic macular edema over a 3-year period achieved rapid improvements in vision and edema.

The financial feasibility of using only one laser for all procedures is a given. Arun C. Gulani, MD, takes this one step further, arguing that perhaps the future may hold cases in which use of the femtosecond laser is a necessity, becoming a standard-of-care concept.

There is a moralistic responsibility that all eye-care professionals should follow to make sure their patients choose the correct eyewear to prevent injury, especially when the patients are children.

Patients with open-angle glaucoma (OAG) had a significant reduction in IOP and did not require anti-glaucoma medications over 1 year postoperatively when micro-invasive glaucoma surgery (MIGS) was performed, according to interim results for a MIGS study group that were reported by David F. Chang, MD.

Bausch + Lomb and TheraPearl LLC have announced the creation of the Bausch + Lomb THERA°PEARL Eye Mask, a product aimed at those suffering from a variety of common ailments, including the most common type of dry eye.

InnFocus Inc. has received authorization from the FDA to begin the phase I trial of the InnFocus MicroShunt to treat open-angle glaucoma (OAG).

Ophthalmologists are nearing a crossroads with the replacement of phacoemulsification by femtosecond laser technology. New femtosecond laser technology is costly, and surgeons must decide if this technology is right for their practices, explained John Vukich, MD.

Alcon Research Ltd. has accused Mylan Inc. of seeking government approval for a drug that would infringe three of its patents for a glaucoma treatment.